Popular Articles

Scientists Search For Sleepless Souls Suffering Lifelong Insomnia, Scotland
Most people have experienced the odd sleepless night before a crucial exam, a job interview or before going on holiday, but few people get by with just a couple of hours of sleep a day, every day.
generic viagra online
Hope For Treatment Of The Metabolic Syndrome Offered By Natural Hormone
Angiotensin 1-7, a hormone in the body that has cardiovascular benefits, improves the metabolic syndrome in rats, according to a new study. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
News of the day
Blogs Comment On Tiller's Murder, Supreme Court Nomination
The following summarizes selected women"s health-related blog entries.~ "The Murder of Dr. Tiller, a Foreshadowing," Cristina Page, Birth Control Watch: Page writes, "For those who would like to think" that the "murder in church of Dr. George Tiller ... is an isolated incident, here"s the horrifying news: You are wrong." She continues, "The pattern is clear and frightening." According to Page, there were several murders of abortion providers and even more attempted murders during the administration of former President Clinton, the first president to support abortion rights. However, during the Bush administration, "not only were there no murders, there were no attempted murders," save for a single bombing of an abortion clinic, according to Page. She writes that Tiller"s murder occurred five months into the administration of President Obama, the nation"s second president who supports abortion rights. Page adds, "One can only conclude that like terrorist sleeper cells, these extremists have now been set in motion. Indeed the evidence is already there. The chatter, the threats, the hate-filled rhetoric, are abundant." According to Page, "The pro-choice movement, specifically our abortion providers, are in the greatest danger of violence when we take power." She adds, "The murder of Dr. Tiller suggests that violence against abortion providers may be far more linked to the power, or lack thereof, antiabortion groups have politically than to laws designed to increase penalties against such acts." Page continues that abortion-rights opponents "will put out carefully worded press statements condemning the murder of Dr. Tiller, as became routine for them during the Clinton years." Page concludes, "But unless the rhetoric they choose from now on becomes careful too -- they may be the enablers of murder and terror" (Page, Birth Control Watch, 5/31).~ "Where Will Women Go Now?" Kate Harding, Salon"s "Broadsheet": "If any good can come of the murder of Dr. George Tiller, ... perhaps it"s the opportunity to have a conversation about the reality of termination in the second and third trimesters," Harding writes. She adds, "Anti-choice activists often cast late-term abortions as the murder of a viable baby at the whim of a woman who doesn"t wish to be inconvenienced, carried out by a doctor who looks at her and sees only cartoon dollar signs." According to Harding, "such misinformation and outright lies about procedures that are in fact rare and only performed when medically necessary are what led anti-choice activists to call Tiller "America"s Doctor of Death" and accuse him of running a "murder mill."" The "reality" is that Tiller helped "women in absolutely desperate circumstances, when almost no one else would," Harding writes, adding, "Since the news of Dr. Tiller"s murder broke, personal narratives from people who used his services have been appearing around the Web." Harding talked to Susan Hill, president of the National Women"s Health Foundation, which referred girls and women to his clinic. Hill said, "We always sent the really tragic cases to Tiller." Harding reports that these included "women diagnosed with cancer who needed abortions to qualify for chemotherapy, women who learned late in their pregnancies that their wanted babies had fatal illnesses and rape victims so young they didn"t realize they were pregnant for months." According to Harding, "The trauma of receiving such a diagnosis is only compounded by the difficulty of obtaining a late-term abortion." Harding asked Hill "where women who need late-term abortions can go now," and says that Hill"s "response was bleak." Hill added that she doesn"t know where she will send "those really tragic cases"(Harding, "Broadsheet," Salon, 6/1). ~ "How I (and Other "Pro-Life" Leaders) Contributed to Dr. Tiller"s Murder," Frank Schaeffer, Huffington Post blogs: "My late father and I share the blame (with many others) for the murder of Dr. George Tiller," Schaeffer writes, adding, "Until I got out of the r
Endocrinology

Can-Fite BioPharma To Initiate Phase I/II Clinical Trial With CF102 For The Treatment Of Hepatitis C Virus

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced that, following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee, a phase I/II clinical trial with CF102 for the treatment of HCV will now start enrolling patients. The trial will investigate the safety and efficacy of CF102 in patients with HCV. This ascending-dose trial will be conducted at the Rabin Medical Center and include 32 patients. HCV is predominantly transmitted through body fluids and less frequently by sexual intercourse, and no vaccines are currently available. About 50% to 85% of HCV infected patients develop a chronic form of the disease, of whom 25% to 76% develop active chronic disease and cirrhosis, which is the leading cause of liver transplantation in Europe and the US and greatly increases the risk of liver cancer. Patients are currently offered drug therapy that generally consists of oral Ribavirin in combination with interferon injections. These drugs have severe adverse events and most patients rapidly become refractory to them. The market size today is more than 3 Billion $ and is estimated to grow to around 8.3 Billion $ on 2012. The Company previously reported that preclinical studies have suggested that the drug is active against HCV via inhibition of NS5, RNA dependent RNA polymerase. CF102 was also found to trigger programmed cell death (apoptosis) of liver cancer cells. The Company recently announced the successful completion of a Phase I clinical study with CF102 under an IND in the US, showing a safety profile and a linear pharmacokinetic behavior of the drug. Prof. Pnina Fishman, CEO of Can-Fite, said that "the initiation of the Phase I/II trial in HCV demonstrates the progress of the company in its clinical development program. Based on the definitive molecular mechanism of CF102 which targets the highly specific enzyme NS5 in the viral replication cycle, we have a great belief in the performance of the drug." In keeping with its financial reports, Can-Fite expects to release within weeks the results of a phase II clinical trial with CF101 for the treatment of Psoriasis. The company concluded successfully a Phase II study in Dry Eye Syndrome. Can-Fite BioPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):